AstraZeneca (AZN.US) Receives Approval in China for the Third Indication of Relizumab
智通财经2026/08/20 09:01Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
```htmlAccording to Zhihu Finance APP, on August 20, the official website of the National Medical Products Administration (NMPA) showed that AstraZeneca (AZN.US)’s "Rilizumab" has been approved for a new indication in China for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Rilizumab was first approved in China in April 2025 for the treatment of adult generalized myasthenia gravis with anti-AChR antibody positivity, and later expanded its indications to NMOSD. This is the third approved indication for this drug in China.```
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Crypto prices
More
Bitcoin
BTC
$71,980.03
+11.90%
Ethereum
ETH
$2,286.01
+19.26%
Tether USDt
USDT
$0.9991
+0.01%
USDC
USDC
$0.9999
+0.01%
XRP
XRP
$1.15
+15.07%
Solana
SOL
$87.5
+13.35%
TRON
TRX
$0.3343
+0.50%
Hyperliquid
HYPE
$73.45
+26.10%
Dogecoin
DOGE
$0.07680
+9.77%
Zcash
ZEC
$561.33
+11.19%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now